An interventional study of Web resources and Personalized outreach in Neoplastic Syndromes, Hereditary, sponsored by University of Washington. Enrolling by invitation at 2 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by University of Washington · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Neoplastic Syndromes, Hereditary with a site in United States — 19 open to participants now, 21 under way, none of them phase 3. Neoplastic Syndromes, Hereditary · United States.
Among the 33 studies in Neoplastic Syndromes, Hereditary with a site in United States, this one is the 7th largest by planned enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2025, is one of 17 with no phase, reaches primary completion later than 5 of the 18 other live ones, and was the 30th registered.
47 studies on the registry are indexed under Neoplastic Syndromes, Hereditary; 26 are open to participants now.
Browse Neoplastic Syndromes, Hereditary studies →19 of the 33 studies in Neoplastic Syndromes, Hereditary with a site in United States are open now. Recruiting first, the newest first:
Columbia University · Sites in United States
Ages 21–75 · Women only
Columbia University · Sites in United States
Ages 18–55 · Women only · Healthy volunteers
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+ · Healthy volunteers
Weill Medical College of Cornell University · Sites in United States
Ages 18–55 · Women only
Shwachman-Diamond Syndrome Alliance Inc · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Neoplastic Syndromes, Hereditary studies recruiting now, 11 (55%) set no upper age limit and 6 (30%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 900 is above the median of 545 across 23 interventional studies indexed under Neoplastic Syndromes, Hereditary.
Median enrollment 588 across the 18 interventional studies, 1,000 across the 15 observational. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 33 have an industry lead sponsor. The 10 most frequent:
University of Washington is the lead sponsor of 1,435 studies on the registry; 225 are open to participants now.
Of its 158 completed or terminated interventional studies of FDA-regulated products, 137 (87%) have results posted.
University of Washington has 1 study filed under Neoplastic Syndromes, Hereditary — fewer than ten, so there is no comparison to draw.
5 of the studies in Neoplastic Syndromes, Hereditary with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05664867University of Illinois at ChicagoImplementation of Population Cancer Genetic Services in Federally Qualified Health Centers (FQHC) | 2026-12 |
| NCT06096688Weill Medical College of Cornell UniversityDiscovering New Targets for Colorectal and Endometrial Cancer Risk Reduction | 2026-12-31 |
| NCT06654466Nest GenomicsClosing the GAPS: Guideline Adherence, Prevention and Surveillance in Hereditary Cancer | 2027-03 |
| NCT07052266Weill Medical College of Cornell UniversityTrial of Combined Obstetric Carrier Screening and Hereditary Cancer Screening | 2027-06 |
| NCT07053813University of WashingtonApplying Population Management Best Practices to Preventative Genomic Medicine Trial | 2027-07-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 33 studies in Neoplastic Syndromes, Hereditary with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Preventive genomic medicine, particularly identification of individuals with inherited cancer risk, can improve longevity and quality of life, yet adherence to risk management following cancer genomic testing is poor. The proposed research refines and evaluates two highly scalable population management interventions, web resources and personalized outreach, designed to improve access and use of recommended risk management following cancer genetic testing. Research activities will be conducted in a vertically integrated health system and federally qualified health center and will address post-testing quality and patient safety concerns that are minimizing patient benefit and slowing investments in real world genomic medicine implementation.
Preventive genomic medicine, particularly identification of individuals with inherited cancer risk, provides health systems with the opportunity to improve longevity and quality of life for their patients. The ability to uncover substantially elevated risk of disease through genomic testing, act to reduce that risk, and improve outcomes while lowering costs has been the longstanding promise of genomic medicine. In the case of inherited cancer, however, adherence to recommended risk management following genomic testing is low. Further, our pilot data suggests that health systems are reluctant to expand cancer genomic testing without a clearer idea of how to manage tested patients over time. Our goal in this application is to address this roadblock to genomic medicine implementation. Specifically, we will demonstrate the benefits that adopting population management interventions following genomic testing can provide health systems, using hereditary cancer as a case example. We will revise and rigorously evaluate two population management interventions (web resources and personalized outreach) that improve timely patient outreach and end-to-end tracking without burdening providers. Web resources is a low-touch intervention that links patients with existing educational resources. Personalized outreach is a high-touch intervention that connects patients with a dedicated care manager to discuss risk management and provide care reminders.
Both interventions are highly scalable and mirror population management programs that health systems have used to support cancer screening, diabetes management, and other evidence-based care for decades. We will compare web resources and personalized outreach to usual care in a pragmatic hybrid type-1 randomized trial that engages patients captured in hereditary cancer registries within two health systems, Kaiser Permanente Northwest (KPNW) and Denver Health (DH). KPNW is a vertically integrated health system and DH is a federally qualified health center, providing two highly unique evaluation settings. Our primary effectiveness outcome is adherence to recommended cancer screening over one year. We will collect secondary implementation outcomes, including the acceptability, appropriateness, feasibility, sustainability, and costs of high- and low-touch intervention approaches. By providing clinical champions with essential data and tools to select and implement population management interventions that address critical gaps in post-testing quality and patient safety, this innovative project will advance preventive genomic medicine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
No intervention
Individuals randomized to web resources will be sent materials refined in Aim 1 (via patient portal and USPS mail) within 1-2 weeks after their birthday. Messages will be sent in English or preferred language noted in the EHR.
Behavioral: Web resources
Individuals randomized to personalized outreach will be contacted by the care coordinator in their birthday month for a brief phone call discussing due and overdue screening. The coordinator will attempt to contact patients up to 3 times to complete the phone conversation before considering them opting out of the intervention. If needed, the coordinator can place orders and pending referrals for PCP signature.
Behavioral: Personalized outreach
Mailed educational resources through portal and USPS mail
Phone call to discuss due and overdue screening and other personalized risk management recommendations
Proportion time covered
Proportion time covered by recommended cancer screening
Time frame: 12 months following randomization
Risk reducing surgery
Proportion completing one or more risk reducing surgery
Time frame: 12 months following randomization
Plan to share: Yes — The University of Washington will create public use de-identified datasets of clinical trial data with an accompanying data dictionary, codes, and other documentation relevant to use.
Supporting information: Study protocol, Statistical analysis plan
Time frame: IDP and supporting information will become available 6 months after the study's completion.
Access criteria: The University of Washington will create Data Use Agreements with organizations that wish to access the dataset and accompanying documents.
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Jul 2027, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neoplastic Syndromes, Hereditary →